The Founder scientists have over 70 years of complementary expertise between them in glycobiology, heparin chemistry, sugar analysis and purification, protein/carbohydrate interactions and screening.
IntelliHep is developing a commercial management plan to exploit its proprietary technologies and licensed IP, with the aim of delivering novel drug leads via its own in-house drug discovery programs, and through strategic partnerships.
Prof. Turnbull is Chief Scientific Officer and a Founder of IntelliHep Ltd. He is an internationally-recognised expert in the field of heparan sulfates with over 30 years experience characterising HS structure, biology and protein interactions.
Dr Edwin Yates is Director of Chemistry and a Founder of IntelliHep Ltd. He is a carbohydrate chemist with 25 years experience in research who currently works at the School of Biological Sciences, University of Liverpool.
Dr Andrew Powell is Director of Biology and a Founder of IntelliHep Ltd. Andy has over 20 years of research expertise in carbohydrate binding proteins, carbohydrate analysis, and carbohydrate-protein interactions.
Interim management support has been provided by MerseyBIO, Ithaka Life Sciences and 2BIO Ltd.
A Scientific Advisory Board is currently being recruited. More details to follow.
IntelliHep is currently recruiting a CEO.
IntelliHep is seeking collaborative partnerships to exploit our novel technologies and IP to advance the discovery and optimization of heparin-based glycans as novel drug leads in specific disease applications. Initial in-house commercialisation plans include lead compounds for Alzheimer’s disease and cancer.
Overcome the obstacles in heparin-based drug discovery by accessing: